Cell Therapy Consumables Market, 2021-2031

Cell Therapy Consumables Market, 2021-2031

According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications. In fact, more than 800 IND applications have been filed for ongoing clinical studies, indicating remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. However, manufacturing of cell therapies is a complex and capital-intensive process fraught with a wide range of challenges. Some of the key concerns of contemporary innovators include raw material supply constraints, current facility limitations, high cost of ancillary materials (buffers, growth factors and media) used in upstream processes, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Further, the onset of recent COVID-19 pandemic has created additional challenges for therapy developers, in terms of procuring the required raw materials, by disrupting well-established supply chains.

Recent reports indicate that the global demand for human serum albumin (a key component of cell culture media for use in a multitude of therapeutic and emerging biotech areas) has increased at an annual rate of 10%-15%. , On the contrary, the use of animal components is highly disregarded by the US FDA, European Medicines Agency (EMA), and other regulatory bodies on the grounds that they pose an undesirable risk of transmitting infectious agents, such as prions (mad cow disease) and virus (HIV), as well as enable high batch-to-batch variation. Consequently, serum-free and xeno-free media have proven to be a promising alternative to serum derived components. In order to produce quality cellular therapies, several drug developers prefer to rely on third-party service providers for the supply of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents. Presently, over 60 service providers are actively engaged in providing consumable / raw material products for the production of cell therapies. The current consolidated market landscape is primarily dominated by the presence of large players, capturing a substantial proportion of the market share. In the recent past, many of the aforementioned service providers have also forged strategic alliances and / or acquired other players, in order to further enhance their respective service offerings. Given that the demand for cell therapies is indubitably rising, the corresponding opportunity for cell therapy consumable service providers is expected to witness steady growth, over the next decade.


SCOPE OF THE REPORT
The “Cell Therapy Consumables Market by Type of Consumable (Kits, Media and Reagents), Type of Cell Therapy (Dendritic Cell Therapy, NK Cell Therapy, Stem Cell Therapy and T-Cell Therapy), Scale of Operation (Clinical and Commercial), Type of End-User (Industry and Non-Industry) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021 – 2031” report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:
 A detailed overview of the overall market landscape of players engaged in offering cell therapy consumables, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, number and location of consumable facilities, type of consumable (kits, media and reagents), type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), application area (research use and therapeutic use), scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry).
 An in-depth company competitiveness analysis of cell therapy consumable service providers based on their product portfolio strength (number of type of consumable, number of unique type of cell therapy, number of consumable facilities and application area), service strength (based on its experience and company size) and number of products offered.
 A detailed brand positioning analysis of prominent industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.
 Elaborate profiles of the key players offering cell therapy consumable products. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.
 An analysis of recent developments within the cell therapy consumable industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.
 A list of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), manufacturing facilities and availability of other cell therapy capabilities.
 An informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells), based on type of cell therapy and key geographical regions.
 An elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.
 An insightful discussion on how the recent COVID-19 pandemic is likely to impact the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated within the cell therapy consumables market, over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2021-2031. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of consumable (kits, media and reagents), [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), [C] scale of operation (clinical and commercial), [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry’s evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary research. For all our projects, we have conducted interviews with various experts in this domain (academia, industry, medical practice and other associations) in order to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include
 Annual reports
 Investor presentations
 SEC filings
 Industry databases
 News releases from company websites
 Government policy documents
 Industry analysts’ views

While the focus has been on forecasting the market till 2031, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED
 Who are the key players, across the world, engaged in offering consumables for cell therapies?
 Which regions have emerged as key hubs in terms of cell therapy consumable related capabilities?
 Which are the most popular media components used for cell therapy consumables?
 What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
 How is the recent COVID-19 pandemic likely to impact the consumables market for cell therapies?
 What are the key challenges associated with cell therapy consumables?
 What is the current, global demand (kits, media and reagents) for cell therapy consumables in the manufacturing process?
 How is the current and future market opportunity likely to be distributed across key market segments?
 What are the anticipated future trends related to consumables market for cell therapies?

CHAPTER OUTLINES
Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of the cell therapy consumables market and its likely evolution in the short to mid-term and long-term.

Chapter 3 provides a general introduction to cell therapies. It further includes a detailed discussion on the development and manufacturing process of cell therapies, along with information on the role of raw materials in cell therapy manufacturing. Furthermore, it provides a brief overview of the different types of cell therapy consumables and key challenges associated with their development.

Chapter 4 provides a detailed overview of the cell therapy consumables landscape. It includes information related to over 60 industry players that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, location of headquarters, location of consumable facilities, type of consumable (kits, media and reagents), type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), application area (research use and therapeutic use), scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry).

Chapter 5 features an insightful company competitiveness analysis, highlighting prominent consumable service providers, taking into consideration service strength of a company (based on its experience and company size), product portfolio (number of type of consumable, number of unique type of cell therapy, number of consumable facilities and application area) and number of products.

Chapter 6 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of strength of service portfolio), highlighting the current perceptions regarding their proprietary brands across different consumable classes.

Chapter 7 provides elaborate profiles of key service providers (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.

Chapter 8 provides detailed analysis of the recent developments and initiatives (partnerships and collaborations, mergers and acquisitions and expansions) that have been undertaken in the cell therapy consumable industry, during the period between 2016 and 2021.

Chapter 9 features an in-depth analysis of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company’s size and its experience in this field), pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development), manufacturing facilities and availability of other cell therapy capabilities.

Chapter 10 provides an informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells), based on type of cell therapy and key geographical regions.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of cell therapy consumables market till 2031. We have segmented the market on the basis of [A] type of consumable (kits, media and reagents), [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy), [C] scale of operation (clinical and commercial), [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World).

Chapter 12 features an elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.

Chapter 13 highlights the effects of the recent COVID-19 pandemic on the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.

Chapter 14 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the cell therapy consumables market, based on the research and analysis described in the previous chapters.

Chapter 15 is a collection of transcripts of interviews conducted with various stakeholders in the industry.

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS
The following companies / institutes / government bodies and organizations have been mentioned in this report.

1. 3P Biopharmaceuticals
2. Accellta
3. Acer Therapeutics
4. Activartis Biotech
5. Adaptimmune
6. Adicet Bio
7. Aduro Biotech
8. Advent Bioservices
9. AGC Biologics
10. AgenTus Therapeutics
11. Agilent Technologies
12. Ajinomoto
13. Akadeum Life Sciences
14. Akron Biotech
15. Allele Biotechnology and Pharmaceuticals
16. Allife Medical Science and Technology
17. Allogene Therapeutics
18. Altor BioScience
19. American CryoStem
20. Amphera
21. AMSBIO
22. Anhui Kedgene Biotechnology
23. ANI Pharmaceuticals
24. apceth Biopharma
25. Applied Biological Materials
26. Arbele
27. Arcline Investment Management
28. Argos Therapeutics
29. Aspire Health Science
30. Astellas Pharma
31. Asterias Biotherapeutics
32. AstraZeneca
33. Atara Biotherapeutics
34. ATCC
35. Athersys
36. Atlantis Bioscience
37. Atreca Therapeutics
38. Aurora Biopharma
39. Austrianova
40. Autolus
41. Avantor
42. AVAX Technologies
43. Axol Bioscience
44. Basic Pharma
45. Baxalta
46. Baxter
47. BD Biosciences
48. Beijing Biohealthcare Biotechnology
49. Beijing Doing Biomedical
50. Beijing Immunochina Medical Science & Technology
51. Beijing Sanwater Biological Technology
52. Beijing Tricision Biotherapeutics
53. Beike Biotechnology
54. Bellicum Pharmaceuticals
55. Bio Elpida
56. BioAtla
57. BioCardia
58. BioCare
59. BioCentriq
60. Bio-Connect
61. Bioinova
62. Biological Industries
63. BioNTech
64. BioRestorative Therapies
65. Bio-Techne
66. bluebird bio
67. Bone Therapeutics
68. BrainStorm Cell Therapeutics
69. Bristol-Myers Squibb
70. C3i (Center of Excellence for Cellular Therapy)
71. Caladrius Biosciences
72. Capricor Therapeutics
73. Captain T Cell
74. CardioCell
75. Carina Biotech
76. CARsgen Therapeutics
77. CAR-T (Shanghai) Biotechnology
78. Cartherics
79. Catalent Biologics
80. Celgene
81. Celixir
82. Cell and Gene Therapy Catapult
83. Cell Applications
84. Cell Biologics
85. Cell Biotech
86. Cell Genesys
87. Cell Therapies
88. Cellaria
89. Cell-Easy
90. Cellectis
91. Cellex Cell Professionals
92. CellGenix
93. Cellin Technologies
94. Cellmed
95. CellMP (A subsidiary of Emmecell)
96. CELLnTEC Advanced Cell Systems
97. CellPraxis
98. CellProtect Nordic Pharmaceuticals
99. CellProthera
100. Cells Online
101. Cellular Biomedicine Group
102. Cellular Engineering Technologies
103. Cellular Therapeutics
104. Celonic
105. Celprogen
106. Celularity
107. Celyad
108. Censo Biotechnologies
109. CHA Biolab
110. Chengdu MedGenCell
111. China Regenerative Medicine International
112. CiMaas
113. Clean Cells
114. CO.DON
115. Cogent Biosciences
116. Cognate BioServices
117. CoImmune
118. Cook MyoSite
119. Corestem
120. Corning
121. Creative Biolabs
122. CRISPR Therapeutics
123. Cyagen Biosciences
124. Cytiva (A subsidiary of Danaher)
125. Cytopeutics
126. CytoSen Therapeutics (Acquired by Kiadis Pharma)
127. Cytovac
128. CyTuVax
129. Daiichi Sankyo
130. DanDrit Biotech
131. DCPrime
132. Delta-Vir
133. Dendreon
134. DiscGenics
135. ElevateBio
136. Eli Lilly
137. Endocyte
138. Eureka Therapeutics
139. Eutilex
140. Ever Union Biotechnology
141. EXUMA Biotech
142. Fate Therapeutics
143. Ferrer Internacional
144. Fibrocell Technologies
145. Five Prime Therapeutics
146. Formula Pharmaceuticals
147. Fortress Biotech
148. Fosun Kite Biotechnology
149. Froceth
150. Fujilfim Cellular Dynamics
151. Fujifilm
152. Gadeta
153. Gamida Cell
154. GC Cell (Formerly known as Green Cross Cell)
155. Gemini Bio
156. GenCure (A subsidiary of BioBridge Global)
157. Genentech
158. GenIbet Biopharmaceuticals
159. Genzyme
160. GigaGen
161. GlaxoSmithKline
162. Global Cell Med
163. Glycostem Therapeutics
164. Gradalis
165. Green Cross
166. GRI Bio
167. Guangzhou Trinomab Biotech
168. Heat Biologics
169. Hebei Senlang Biotechnology
170. Hemostemix
171. HengRui YuanZheng Bio-Technology
172. HiMedia Laboratories
173. Histocell
174. Histogenics
175. Holostem Terapie Avanzate
176. Hunan Zhaotai Yongren Biotech
177. IBA Lifesciences
178. iCarTAB BioMed
179. iCell Gene Therapeutics
180. Immatics
181. Immune Therapeutics
182. Immunicum
183. ImmunoCellular Therapeutics
184. Immunocore
185. Immunovative Therapies
186. Immutep
187. IncoCell Tianjin (wholly-owned subsidiary of Boyalife Group)
188. Incysus
189. Innoprot
190. Innovative Cellular Therapeutics
191. Inovio Pharmaceuticals
192. inRegen
193. Intellia Therapeutics
194. International Stem Cell Corporation
195. InVitria
196. Iovance Biotherapeutics
197. Irvine Scientific (Acquired by FUJIFILM)
198. ISTO Technologies
199. Ivy Life Sciences
200. iXCells Biotechnologies
201. Janssen
202. Japan Tissue Engineering
203. Juno Therapeutics
204. JW Biotechnology
205. JW CreaGene
206. Kadimastem
207. Kangstem Biotech
208. KBI Biopharma
209. Kiadis Pharma
210. Kiromic
211. Kite Pharma
212. Kuur Therapeutics
213. LAgen Laboratories
214. Laurus Bio (Formerly known as Richcore Lifesciences)
215. Laurus Labs
216. Legend Biotech
217. Leucid Bio
218. Lifecells
219. Lineage Cell Therapeutics
220. Lion TCR
221. Living Pharma
222. Longeveron
223. Lonza
224. Lumos Pharma
225. Lykan Bioscience
226. Marino Biotechnology
227. MaxCyte
228. Medeor Therapeutics
229. Medigene
230. MEDINET
231. MEDIPOST
232. MedVax Technologies
233. Merck Serono
234. Mesoblast
235. Miltenyi Biotec
236. Minaris Regenerative Medicine
237. Minerva Biotechnologies
238. Minovia Therapeutics
239. MolecuVax
240. Moraga Biotechnology
241. Multimmune
242. Mustang Bio
243. Nanjing KAEDI Biotech
244. NantKwest
245. Neopharm
246. Neuralstem
247. Neuromics
248. Nikon CeLL innovation
249. Nkarta
250. Nohla Therapeutics
251. Noile-Immune Biotech
252. Northern Therapeutics
253. Northwest Biotherapeutics
254. Novadip Biosciences
255. Novartis
256. NovaRx (Acquired by Viropro)
257. Novella Clinical
258. Novex Innovations
259. Nucleus Biologics
260. Nuo Therapeutics
261. OhioHealth
262. OiDE BetaRevive
263. Ology Bioservices
264. Oncobiomed
265. Opexa Therapeutics
266. Orchard Therapeutics
267. OrganaBio
268. Osiris Therapeutics
269. Oxford BioMedica
270. PAN-Biotech
271. PDC*line Pharma
272. PELOBiotech
273. PeproTech
274. PersonGen BioTherapeutics
275. Pfizer
276. PharmaBio
277. Pharmicell
278. PhoenixSongs Biologicals
279. Pinze Lifetechnology
280. Pique Therapeutics
281. Pluristem Therapeutics
282. Plus Therapeutics
283. Poseida Therapeutics
284. Precigen
285. Precision BioSciences
286. Preferred Cell Systems™
287. Pregene ShenZhen Biotechnology
288. Primorigen Biosciences (Acquired by Nucleus Biologics)
289. ProMab Biotechnologies
290. Promethera Biosciences
291. PromoCell
292. Provia Laboratories
293. R&D Systems (Formerly known as Atlanta Biologicals)
294. ReachBio Research Labs
295. Regeneris Medical
296. Regeneron
297. Regeneus
298. ReNeuron
299. REPROCELL
300. Rexgenero
301. RHEACELL
302. Riyadh Pharma
303. RoosterBio
304. Roslin Cell Therapies
305. Rubius Therapeutics
306. S.Biomedics
307. Sangamo Therapeutics
308. Sanvitra
309. Saronic Biotechnology
310. Sartorius
311. ScienCell Research Laboratories
312. Sclnow Biotechnology
313. SCM Lifescience
314. Seattle Genetics
315. Sentien Biotechnologies
316. Servier
317. Shanghai Bioray Laboratory
318. Shanghai GeneChem
319. Shanghai Houchao Biotechnology
320. Shanghai iCELL Biotechnology
321. Shanghai Longyao Biotechnology
322. Shanghai Unicar-Therapy Bio-medicine Technology
323. Shenzhen BinDeBio
324. Shenzhen Hornetcorn Biotechnology
325. Shionogi
326. Sigma-Aldrich (Acquired by Merck)
327. Sinobioway Cell Therapy
328. SMT Bio
329. Sorrento Therapeutics
330. SOTIO
331. SQZ Biotech
332. Stem Cell Arabia
333. STEMCELL Technologies
334. StemImmune
335. Stemmatters
336. Sumitomo Dainippon Pharma
337. Super-T Cell Cancer Company
338. Surface Oncology
339. Tactiva Therapeutics
340. Taiwan Bio Therapeutics
341. Takara Bio
342. Takeda Pharmaceutical
343. TapImmune
344. Targazyme
345. TC BioPharm
346. TCR2 Therapeutics
347. Tella
348. Tessa Therapeutics
349. The Discovery Labs Center for Breakthrough Medicines
350. Thermo Fisher Scientific
351. ThermoGenesis
352. Tianhe Stem Cell Biotechnologies
353. TiGenix
354. TILT Biotherapeutics
355. Tmunity Therapeutics
356. TNK Therapeutics
357. TotipotentRX
358. TRACT Therapeutics
359. TransCure BioServices
360. TreeFrog Therapeutics
361. Trinova Biochem
362. Triumvira Immunologics
363. TVAX Biomedical
364. Universal Cells
365. U.S. Stem Cell
366. Vaccinogen
367. Vericel
368. VetStem Biopharma
369. ViroMed
370. Viscofan BioEngineering
371. Vitro Biopharma
372. Waisman Biomanufacturing
373. West Biotherapy
374. Wissenschaftlicher Service Pharma (WiSP)
375. Wuhan Sian Medical Technology
376. WuXi AppTec (WuXi Advanced Therapies)
377. Xcell Therapeutics
378. Xcelthera
379. XEME Biopharma
380. Zelluna Immunotherapy
381. Zimmer Biomet
382. Ziopharm Oncology

Please note that the publisher limits purchases by consulting clients to either Consulting Company Team License or Global Site License for Entire Company. Any other selections will not be fulfilled by this publisher.